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Abstract 
Lithium is a first-line therapy for bipolar affective disorder. However, various adverse effects, 
including a Parkinson-like hand tremor, often limit its use. The understanding of the 
neurobiological basis of these side effects is still very limited. Nigral iron elevation is also a 
feature of Parkinsonian degeneration, which may be related to soluble tau reduction. We found 
that MRI T2 relaxation time changes in subjects commenced on lithium therapy were consistent 
with iron elevation. In mice, lithium treatment lowers brain tau levels and increases nigral and 
cortical iron elevation that is closely associated with neurodegeneration, cognitive loss and 
parkinsonian features. In neuronal cultures lithium attenuates iron efflux by lowering tau protein, 
which traffics amyloid precursor protein to facilitate iron efflux. Thus, tau- and APP- knockout 
mice were protected against lithium induced iron elevation and neurotoxicity. These findings 
challenge the appropriateness of lithium as a potential treatment for disorders where brain iron is 
elevated (e.g. Alzheimer’s disease), and may explain lithium-associated motor symptoms in 
susceptible patients. 
Key words: Tau; Lithium; Parkinson’s disease; Iron; Bipolar affective disorder, 
Neuroprotection, Neurodegeneration 
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Introduction 
Lithium was identified as a psychoactive drug in the mid-20th century1, and remains the 
primary therapy for bipolar affective disorder 2 (although it is often used in other psychiatric 
disorders also). Unfortunately it has a narrow therapeutic window limited by adverse effects3, 4, 
and neither the mechanism of action nor its associated toxicity are well understood. Lithium 
modulates multiple key cellular signaling molecules3, 5, including inositol monophosphatase 
(IMPase) and glycogen synthase kinase 3 (GSK-3), considered likely to be therapeutic targets3. 
Parkinson-like hand tremor is a common adverse effect of lithium therapy, and limited cross-
sectional studies and several case reports have raised concern that lithium may increase the risk 
for extra-pyramidal syndromes (e.g. dyskinesia) in overdose, but possibly also at appropriate 
maintenance levels6-15. Recently, long-term lithium use was reported as associated with an 
increased incidence of antiparkinson drug use or a PD diagnosis16. Whether lithium could induce 
extra-pyramidal syndromes by neurotransmitter imbalance (like 1st generation antipsychotics 
such as haloperidol) or by damage to the basal ganglia is not known. 
While a previous study demonstrated the neurotoxic potential of lithium in mice treated with 
a dose considered to be within the therapeutic range (2.55g/kg in food)17, lithium has been more 
extensively investigated for a host of neuroprotective properties in various neurological and 
psychiatric models including cerebral ischemia/reperfusion injury18 and other neurotoxic 
insults19. A recent study19 of adolescents at ultra-high risk for psychosis20 found that low dose 
lithium treatment over 4 months lowered hippocampal T2 relaxation time (T2*), which was taken 
to signify neurochemical improvements that could underlie potential neuroprotective benefits of 
low-dose lithium as an approach to prevent the onset of psychosis21, 22. However, a reduction of 
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T2* can also be caused by an elevation of brain iron, and has been used to map such changes in 
diseases where iron levels rise, such as cortical tissue in Alzheimer’s disease (AD)23. 
Lithium has attracted considerable interest as a therapeutic candidate in AD research. In 
neuronal cultures, lithium is reported to decrease tau phosphorylation24-27 and to inhibit A 
generation28-30. In A-overexpressing transgenic models for AD, lithium treatment consistently 
decreases A levels, GSK-3 activity and tau phosphorylation29, 31-34. In such models, lithium is 
reported to prevent A toxicity32, preserve dendritic structure31, promote neurogenesis34 and 
rescue A-induced cognitive impairment31, 33, 34. Similarly, in transgenic mice that overexpress 
pathogenic mutant tau, lithium treatment reduced levels of hyperphosphorylation35-39. Despite 
these promising pre-clinical findings, lithium failed to show therapeutic efficacy for AD in a 10-
week multicenter, randomized, single-blind, placebo-controlled trial, with no significant effects 
on CSF A, CSF phospho-tau, or cognitive endpoints40. 
Nevertheless, lowering total tau expression is still being explored as a potential treatment for 
AD, and lithium is still being considered as a treatment option since it lowers both tau protein 
and mRNA levels in cultured cortical neurons41, 42. Supporting this concept, long-term (5 
months) lithium treatment of PrP T44 tau transgenic mice resolved tau aggregates by promoting 
ubiquitination and degradation of tau, rather than altering GSK-3 activity36.  
We, and others, have reported concerns that lowering levels of brain tau could induce age-
dependent neurodegeneration43-45. In tauopathies (such as AD and Parkinson’s disease (PD)), 
insoluble tau aggregates are accompanied by a fall in soluble tau levels in affected tissue43, 46-51. 
We have argued that this will lead to a loss of tau function that could cause neurodegeneration, 
since tau functions to lower neuronal iron levels by promoting the presentation of the amyloid 
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protein precursor (APP) to the neuronal surface43, where it promotes the efflux of iron52-54. 
Without soluble tau, neurons accumulate iron to toxic levels, and so, tau knockout mice develop 
a parkinsonism with impaired-cognition phenotype that is rescued by iron chelation43, 44. Iron 
accumulation in the substantia nigra (SN) is a robust feature of PD, and is a sufficient cause for 
parkinsonism (reviewed55). There has been one case report of such SN iron elevation with 
extrapyramidal signs following long-term lithium treatment56. We hypothesized that, since 
lithium lowers neuronal tau, lithium could engender SN iron accumulation and induce 
parkinsonian neurodegeneration, explaining a cryptogenic aspect of its adverse effects profile. 
Materials and methods 
Reagents. Reagents were purchased from Sigma, Australia, unless specified. 
The lithium clinical imaging study. The lithium clinical imaging study has been previously 
described19. The pilot study was conducted as an open-label, non-randomised, controlled single 
center study. Participants were consecutive referrals to the Personal Assessment and Crisis 
Evaluation (PACE) Clinic, a specialist clinic for young people at ultrahigh risk (UHR) for 
psychosis20. PACE is a subprogram of ORYGEN Youth Health, a specialist service for young 
people with emerging mental disorders. Inclusion criteria for PACE were: (1) age between 14 
and 30 inclusive, (2) resident of the Melbourne metropolitan area or the ability to travel to the 
PACE clinic at least once a week, and (3) meeting PACE UHR criteria. UHR criteria were 
determined using the Comprehensive Assessment of the At Risk Mental State (CAARMS)57. 
Rationale and validity for these criteria have been fully described elsewhere58. Exclusion criteria 
were: (1) medical or neurological conditions that may diminish functioning or that may account 
for some of the symptoms leading to the initial referral e.g. epilepsy, (2) clinically relevant 
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biochemical or hematological abnormalities, (3) serious coexisting illnesses such as liver or renal 
insufficiency, significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological 
or metabolic disturbances (including patients known to be HIV positive), (4) history of previous 
acute psychotic episodes either treated or untreated, (5) a current score of 5 or 6 on the 
CAARMS Mania item or a history of a previous manic episode, (6) any previous use of 
neuroleptic or mood stabilizing medications, (7) history of severe drug allergy or 
hypersensitivity, (8) history of intellectual disability (IQ < 70), (9) inability to understand or 
communicate in English. All UHR subjects received PACE treatment as usual throughout the 
course of the study including psychological and medical treatment. Use of antidepressants was 
allowed if UHR patients met criteria for major depression. UHR subjects in the low-dose lithium 
group took one slow-release 450 mg tablet of lithium carbonate each night for the entire study 
period (3 months), intended to achieve serum lithium levels of 0.3- 0.5 mM, in addition to 
treatment as usual. 
Baseline MRI scans and clinical assessments were conducted prior to commencement of the low-
dose lithium treatment, and within two weeks of admission to the study. Monitoring of 
psychopathology and tolerability measures occurred at monthly intervals, and follow-up 
scanning was conducted as close as possible to three months after baseline (median for the 
control group was 3.0 months, range 0.8-27 months; for the lithium group 3.8 months, range 1.6-
5.9 months, some subjects in both groups not completing the full treatment period). 
Extrapyramidal side effects were not systematically assessed. The local research and ethics 
committee approved the study protocol. All participants gave written informed consent. 
Additional written informed consent was obtained from parents or guardians for participants 
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aged 14 - 18. Participants were made aware that they could withdraw from the study at any time 
and that withdrawal would not compromise access to any clinical services.  
Brain imaging and SN T2 relaxometry. All scans were performed on a 3T GE LX Horizon 
scanner (GE Healthcare, Milwaukee, USA) at the Brain Research Institute, Victoria, Australia. 
Eight tilted, coronal T2-weighted images (perpendicular to the long axis of the hippocampus) 
were obtained over a range of echo times (29 to 231msec; TR=4sec, slice thickness= 6mm with 
1.5mm gap, matrix 256x256, FOV 24cm). Single exponentials were then fitted to the image data 
of corresponding voxels from these eight echoes using iBrain (Brain Research Institute, 
Melbourne). This created a series of T2 maps, one for each coronal slice. The brightness of each 
individual voxel on this map represents its calculated T2 relaxation time. The images were then 
analyzed in various regions of interest with reference to a standard neuroanatomical atlas, by two 
raters who were blinded to treatment group, and quantified using ANALYZE 7.2 software 
(Mayo Clinic, Rochester, Minn), as described19. 
Primary neuron culture. Primary neurons were prepared as previously described43. Briefly, 
cortices of wild type and tau knockout embryos (day 14) were dissected and dissociated in 
0.025% (w/v) trypsin. The neurons were plated (Nunc) at a density of 600,000 cells per cm2 in 
plating medium (DMEM with 10% fetal calf serum, 5% house serum, and 10 mg L–1 gentamycin 
sulfate, Invitrogen). After 2 h incubation, the neurons were changed to Neurobasal supplemented 
medium (with B27, 500 M glutaMAX and 10 g mL–1 gentamycin sulfate). Experiments were 
performed 7 d later. Confluent cells were incubated in Neurobasal medium solution before 
treatment with various concentrations of lithium chloride for 18 hours with or without 
radioactive 59Fe or 65Zn, or various compounds (L690,330; 6-bromoindirubin-3'-oxime, BIO) at 
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concentrations indicated. The cells were then harvested, with half the batch lysed using lysis 
buffer (1% Triton-X100, 50mM Tris-HCl, 150mM NaCl, 1mM EDTA, pH7.4 together with 1:50 
proteinase inhibitor and 1:1000 kinase inhibitor I&II), and the other half retained for metal 
analysis (see below), or assayed for radioactive tracers by γ-counter. 
59Fe-loaded transferrin and 65Zn preparation. Purified human apo-transferrin (Tf) was loaded 
with 59Fe (PerkinElmer), to form Tf(59Fe)2 as described 43, 52. Neurons were incubated with 1.0 x 
10-6 M Tf(59Fe)2 in serum-free Neurobasal supplemented medium for periods indicated. At the 
conclusions of the treatments, neurons were washed thoroughly with PBS, and harvested with 
trypsin. All media and cell lysates were measured by γ-counter (Wizard 3, Perkin Elmer) for 
counts/min (CPM). For iron efflux assay, cells were incubated at 37˚C and medium was removed 
at select time points. A comparable time course control study was performed at 4˚C to account 
for non-specific binding of 59Fe to the membrane surface.  
65Zn experiments were adapted from a previous publication59. Briefly, serum-free 
Neurobasal supplemented medium was mixed with 0.04M Bq 65Zn (Oak Ridge Laboratory) and 
unlabeled ZnCl2 (20 M). After 18 hours of treatment, the reaction was stopped by washing cell 
monolayers three times with ice-cold non-labeled HBSS (with 2 mM L-histidine and 5 mM 
EDTA). The cells were then harvested and measured for 65Zn retention by γ-counter (1282 
CompuGamma, LKB Wallac). 
Mouse tissue preparation. All mice were housed in a conventional animal facility according to 
standard animal care protocols and fed standard laboratory chow (Meat Free Rat and Mouse 
Diet, Specialty Feeds, Australia) and tap water ad libitum. All animal procedures were approved 
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by the Florey Institute animal ethics committee (10-017) and were performed in accordance with 
the National Health and Medical Research Council guidelines. Tau knockout60, APP knockout52 
and background C57Bl6/SV129 mice stocks raised under the same conditions, were maintained 
homozygously, with backcrossing to the parental inbred strain every 3 generations. The mouse 
was euthanized with an overdose of sodium pentobarbitone (Lethabarb, 100mg/kg) and perfused 
with ice-cold saline before tissues were collected. Body weight and total brain wet weight were 
recorded. Once extracted, the right brain hemisphere was micro-dissected and stored at -80°C 
until required. The left brain hemisphere was fixed in 4% paraformaldehyde for 24 h, and then 
transferred to 30% Sucrose + PBS (pH 7.4) and kept at 4°C overnight for tyrosine hydroxylase 
(TH) immunohistochemistry and brain section analysis. 
Lithium treatment to mice. 3-month-old male Bl6/C57J mice (used in Figure 2) as well as age-
matched tau knockout, APP knockout, and background control (BL6/129sv) mice (used in 
Figure 4) were randomly assigned (by Excel) and orally gavaged with lithium chloride 
(3.6mg/kg/day, freshly dissolved in 0.9% NaCl, 0.5% Na-carboxymethylcellulose, 0.5% benzyl 
alcohol, and 0.4% Tween-80, with the use of an oroesophageal needle, continuously for 21 days) 
or the solution alone. Behavioral tests were performed at Day18-21, 2 hours after the daily 
lithium dose. To control for effects of potential acute sedation, drug-naive Bl6/C57J mice were 
treated with a single dose of diazepam (3mg/kg) or lithium (3.6mg/kg) and the performance tests 
carried out 2 hours later. 
Behavioral measurements: Pole test assessment was performed as previously described43. 
Briefly, mice were placed vertically on a 30 cm vertical, 1 cm diameter pole placed within in 
their home cage, where mice make an 180˚ turn and return to the base of the pole. On the day 
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prior to testing (day 1), the animals were habituated to the pole and allowed five consecutive 
trials. Animals were then recorded via digital video on the test day (day 2). The interval time for 
the mouse to turn toward the ground (‘time to turn’), and to reach the ground (‘time to finish’) 
were both recorded. Each mouse underwent five trials and the average was used in analysis. 
When mice were unable to turn and move down the pole, the trial was determined as incomplete. 
Rotarod assessment was performed as previously described43. Briefly, mice were assessed using 
a Panlab Rotarod apparatus in an accelerating model with triplicate measurements (maximum 
time of 2.5 min; speed increases every 8s). The time on the rod as well as the final speed of the 
rod was recorded and the triplicates averaged for analysis. Open field test. Spontaneous motor 
activity of mice was measured using a photo-beam activity system (Truscan 2.0, Coulbourn 
Instruments) as previously described43. The test area was 25.4 cm wide by 25.4 cm deep by 40.6 
cm high. The mouse was placed in the chamber for one hour to allow acclimatization to its 
surroundings. Parameters of movements were calculated from the interception of beams to 
provide an XY coordinate. For Y maze test, a Y-shaped grey-painted timber with arms 29.5 cm 
long × 7.5 cm wide × 15.5 cm high was used as previously described43. All mice were subjected 
to a 2-trial Y-maze test separated by a 1 h intertrial interval to assess spatial recognition memory, 
with all testing performed during the light phase of the circadian cycle. The 3 identical arms 
were randomly designated start arm, novel arm, and other arm. Visual cues were placed on the 
walls of the maze. The first trial (training) was for 10 min, and the mice were allowed to explore 
only 2 arms (starting arm and other arm). For the second trial (retention) mice were placed back 
in the maze in the same starting arm, and allowed to explore for 5 min with free access to all 3 
arms. Behaviours were recorded on video during a 5 min trial and the Ethovision video-tracking 
system (Noldus, Netherlands) was used for analysis. Data are expressed as the percentage of 
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frequency and duration for novel arm entries made during the 5-min second trial. All behavioural 
tests were performed by an investigator blinded to the experimental group. 
Anatomical morphology from brain slice. The anatomical morphology was examined as 
previously described43. Briefly, caudate/putamen (CPu) and cerebellum sections from mice were 
sectioned using a Leica Cryostat set at 50 μm thickness and areas of interest were measured 
using Image-J (v1.49b, NIH), using landmarks (anterior commissure for CPu, and flocculus for 
cerebellum) to identify the depth of coronal sectioning (bregma +0.26±0.01mm and 
bregma -6.12±0.01mm). Two sections per mouse per area were analysed. CPu area was defined 
by the boundaries of corpus callosum, lateral ventricle, and anterior commissure. Corpus 
callosum, neocortical and cerebellar cortical thicknesses were averaged from 5 measurements. 
All quantifications were blinded. 
Tyrosine hydroxylase immunohistochemistry. Tyrosine hydroxylase (TH) immunohistochemistry 
was performed as previously described43. On a calibrated Leica Cryostat, 30 μm sections (1:3 
series) were collected through the SN pars compacta (SNpc) (anteroposterior -2.92 to -3.64 mm 
from bregma, Mouse Atlas Figure 55 to Figure 61), generating 8 sections per mouse (the second 
of the three sections was analyzed). After a further brief fixation (4% paraformaldehyde for 30 
seconds), sections were blocked in 3% normal goat serum (Millipore) and incubated with 
primary anti-TH rabbit polyclonal (1:3000, Millipore) overnight. The sections were then 
incubated with goat anti-rabbit secondary horse radish peroxidase-conjugated antibody for 3 
hours (Millipore), followed by diaminobenzidine visualization (1% w/v in PBS + 1% w/v CoCl2, 
1% w/v NiSO4) + 3% w/v hydrogen peroxide. TH immunostained sections were counter-stained 
 13
with Neutral Red to visualize the Nissl substance in all neurons before mounting on Superfrost-
Plus slides. 
Stereological estimation of nigra neurons. SN neuron number was estimated as previously 
described43. Briefly, both TH-positive and TH-negative, Nissl-positive neurons were scored 
according to the optical fractionator rules by an investigator blinded to the experimental group. 
Using an unbiased counting frame (x=35 μm, y = 45 μm) at regular intervals on a sampling grid 
(x=140 μm, y=140 μm), viewed through a 60 x 1.3 N.A. oil objective (DMLB Leica 
Microscope), cells were detected with a morphometry and design-based stereology software 
package (Stereo Investigator 10.04, Microbrightfield, Colchester, VT). The coefficients of error 
and coefficients of variance were calculated as estimates of precision and only values of <0.1 
were accepted. 
Dopamine and DOPAC measurement. Dopamine metabolites were measured as previously 
described43. Briefly, CPu tissues were homogenized in HPLC sample buffer (0.4M perchloric 
acid, 0.15% sodium metabisulfite and 0.05% EDTA) before centrifugation at 10,000 g at 4 ˚C for 
10 minutes. Supernatants were used for dopamine measurement by a HPLC system (ESA 
Biosciences; model 584) coupled to an electrochemical detector (ESA Biosciences; Coulochem 
III detector) (E1:-150 mV, E2:+220 mV, and guard cell: +250 mV). 50 µL was injected onto a 
MD-150 reverse phase C18 column (ESA Biosciences) and elution was performed at a flow rate 
of 0.6 mL/min in the mobile phase (75 mM sodium dihydrogen phosphate, 1.7 mM 1-
octanesulfonic acid sodium salt, 100 mL/L triethylamine, 25 mM EDTA, 10% acetonitrile, pH 
3). Peaks were identified by retention times set to known standards. Data were normalized to wet 
weight tissue. 
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Metal Analysis. Metal content was measured as previously described43. Briefly, samples from 
each experimental condition were freeze-dried, and then re-suspended in 69% nitric acid 
(ultraclean grade, Aristar) overnight. The samples were then heated for 20 min at 90 ˚C, and an 
equivalent volume of hydrogen peroxide (30%, Merck) was added for a further 15 min 
incubation at 70 ˚C. The samples were diluted in double-distilled water and assayed by 
inductively coupled plasma mass spectrometer (Ultramass 700, Varian). Each sample was 
measured in triplicate and the concentrations determined from the standard curve were 
normalized to tissue wet weight. 
Western Blot. Samples from each experiment were homogenized in PBS (pH=7.4) with EDTA-
free protease inhibitor cocktail (1:50, Roche) + phosphatase inhibitors I and II (1:1000) and 
centrifuged at 100,000 g for 30 minutes. Protein concentration of the supernatant following 
centrifugation was determined by BCA protein assay (Pierce). Aliquots of soluble tissue fraction 
with equal protein concentrations were separated in 4-12% bis-Tris gels with NuPAGE MES 
running buffer (Invitrogen), and transferred to nitrocellulose membranes by iBlot (Invitrogen). 
The membranes were blocked with milk (10% w/v) and probed with appropriate primary and 
secondary IgG-HRP conjugated antibodies (Dako). Enhanced chemiluminescence detection 
system (GE Healthcare) with the Fujifilm LAS-3000 was used for visualization. Densitometric 
quantification of immunoreactive signals was performed by ImageJ (1.49b, NIH) and normalized 
to the relative amount of -actin and expressed as a percentage of the mean of the control group. 
The following primary antibodies were used in the current study: anti--actin (Sigma), anti-tau 
(DAKO), anti-pTau396 (Invitrogen). 
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Statistics. Statistical analysis was carried out in Prism 6 (GraphPad Software Inc) and power 
calculations were performed using PASS 13 (trial version, NCSS Statistical Software, USA) 
based on the variance of results in our previous publication10 and in pilot experiments. 
Equivalence of variance between experimental groups was confirmed using a Levene’s test, 
when applicable. Normal distribution was assumed for all statistical analyses. All tests were two-
tailed, with the level of significance set at 0.05. Specific types of test used for each experiment 
are described in Figure legends.  
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Results 
Low dose lithium treatment induces reversible T2* changes in the substantia nigra consistent 
with iron elevation 
To determine whether lithium treatment has the potential to raise nigral iron levels, we 
analyzed this nucleus in scans from a previous clinical trial19. The impact of low dose lithium 
treatment on hippocampal tissue integrity in individuals at UHR for psychosis was assessed by 
T2 relaxometry in an open-labeled, non-randomized, controlled, single center pilot study. 
Participants were treated with lithium or as usual for three months, and repeated 3T magnetic 
resonance images were taken from participants before commencement of the study (Scan one), 
and after drug withdrawal (Scan two). Lithium treatment induced a decrease in hippocampal T2 
relaxation time19, which could indicate an improvement in various neuropathologies (e.g. edema) 
but could also reflect an increase in tissue iron61-65. 
Since iron elevation in the SN could contribute to Parkinson-like side effects such as the 
commonly observed hand tremor, we revisited this study and measured T2 relaxation in this 
region, as well as other comparison regions in the same coronal planes (as marked in 
Supplementary Figure 1a, with reference to a standard neuroanatomical atlas). We found that 
the average T2 relaxation time in the SN of the lithium group at three months (Scan two) was 
significantly reduced from baseline (Scan one) (-5%, p = 0.007), and significantly lower than the 
control (treatment as usual) group at the same time point (-7%, p < 0.001; Figure 1a-b), 
consistent with iron accumulation or edema. The pattern of changes was similar in both 
hemispheres. Other regions analyzed, caudate and lenticular nucleus (LN), showed no change in 
T2 relaxation time (p = 0.18 for caudate; p = 0.29 for LN; Supplementary Figure 1b) compared 
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to the baseline scan. The lateral ventricular cross-sectional area (LV) was also unchanged from 
baseline (p = 0.177; Supplementary Figure 1b).  
Iron accumulation and parkinsonism in a mouse model of lithium therapy 
To test whether lithium-induced relaxometry changes could be due to brain iron accumulation, 
3-month old C57/Bl6J mice were orally administered lithium chloride at a low therapeutic dose40 
(3.6mg/kg body weight/day) for 21 days. The dose was well-tolerated and body weight was 
unaltered during the treatment period (p = 0.188; Figure 2a). Lithium levels were elevated in all 
tested tissues (p<0.001 for cortex, SN, cerebellum, and liver), with the greatest proportional 
elevation in cortex (+263%) and SN (+152%; Figure 2b). Iron levels were increased in cortex 
(+40%, p=0.008) and SN (+19%, p=0.039), but not cerebellum, liver or plasma (Figure 2c). The 
effect of lithium on biological metals was specific to iron, with copper and zinc unaltered in all 
tested tissues (Supplementary Figure 2a-b). Lithium levels significantly correlated with iron 
levels in SN (p = 0.007, R2= 0.62; Figure 2d) and cortex (p = 0.026, R2= 0.439; Supplementary 
Figure 3a) in lithium-treated mice, consistent with elevated lithium causing an elevation in iron. 
The correlation was seen neither in sham-treated SN (R2= 0.02; Figure 2d) nor cortex (R2= 0.03; 
Supplementary Figure 3a), nor observed in the cerebellum of lithium- (R2= 0.01) or sham-
treated (R2= 0.05) animals, a region that did not accumulate iron with lithium treatment 
(Supplementary Figure 3b). Neither copper nor zinc correlated with lithium in these tissues 
(Supplementary Figure 3c-d).  
We assessed the brains of lithium-treated mice to determine whether a drop in soluble tau 
could explain the iron elevation43. As expected36, 38, 39, 66, the fraction of brain tau phosphorylated 
at Ser396 was suppressed by lithium treatment (cortex: -40%, p = 0.034; SN: -43%, p = 0.039; 
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Supplementary Figure 4). We also discovered that lithium administration lowered PBS-soluble 
total tau levels in cortex and SN (cortex: -31%, p = 0.032; SN: -42%, p < 0.001; Figure 2e). 
Since tau loss causes iron-mediated neurodegeneration with parkinsonism43-45, we investigated 
whether the lithium treatment impaired motor function in these mice. Lithium-treated mice 
compared to sham-treated mice exhibited a significant increase in time to turn (p = 0.008; Figure 
2f) and to finish (p = 0.041; Supplementary Figure 5a) on the Pole test, and significantly 
impaired performance on the accelerated Rotarod test as evidenced by reduced latency to fall (p 
= 0.004; Figure 2g), and lower average speed to fall (at speed 6, p<0.001; at speed 7, p=0.015; 
Supplementary Figure 5b). Rotarod impairment has previously been noted in 10 month old 
mice treated for 4 weeks with lithium, but the cause was not ascertained39. Lithium-treated mice 
also exhibited reduced locomotion distance (p = 0.022; Supplementary Figure 5c), reduced 
velocity (p = 0.023; Supplementary Figure 5d), and reduced average distance per movement (p 
= 0.018; Supplementary Figure 5e), without alterations in movement duration or time spent in 
the corners (data not shown) in the Open field test. 
Control studies were performed to ascertain whether short-term sedation4, 67 could have 
contributed to the motor impairment induced by lithium. Diazepam, a sedative with well-
characterized effects on motor behaviors68-71, was compared to lithium within 2 hours after dose 
for acute motor behavioral effects. Single-dose lithium or diazepam did not impair mouse 
Rotarod performance at this interval (Supplementary Figure 6a). Diazepam, but not lithium, 
induced a sudden drop in spontaneous locomotion 20 mins after dosing in the Open field test (p 
= 0.006; Supplementary Figure 6b). These data indicate that the motor impairments induced by 
lithium were not due to sedation. 
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To determine whether the motor deficits induced by lithium could be due to Parkinson-like 
neuropathology, the TH-immunoreactive (dopaminergic) neurons within the SN were 
stereologically counted. The dopaminergic neurons were significantly decreased in mice treated 
with lithium for 21 days (-30%, p < 0.001; Figure 2h-i), but TH-negative, Neutral Red-positive 
neurons were unaltered (Supplementary Figure 7a). Accompanying this loss, dopamine (-40%, 
p = 0.023; Figure 2j) and DOPAC (-37%, p = 0.024; Supplementary Figure 7b) levels in the 
striatum were also decreased in lithium-treated mice. Excess dopamine induces hyperactivity, a 
characteristic of mania72, and is attenuated by lithium treatment73. Lithium decreases 
dopaminergic release74 and suppresses levels of dopamine and its metabolites in the striatal 
projection field and nucleus accumbens75. Our findings indicate that suppression of the SN-
striatal dopaminergic pathway may contribute both to the motor deficits induced by lithium, as 
well as, potentially, to its long-term anti-manic and anti-psychosis properties. 
Lithium induces tau-mediated iron accumulation in neuronal culture 
Having found that by inducing nigral tau suppression lithium treatment of normal mice 
recapitulated a series of abnormalities that appear in tau knockout mice (nigral iron elevation 
with dopaminergic neurodegeneration and parkinsonism), we investigated the mechanism in 
mouse primary cortical neuronal cultures. Lithium (at non-toxic concentrations29) induced 
significant iron accumulation within 18 hours in a dose-dependent manner (5mM Li: +48%, p = 
0.005; 10mM Li: +56%, p < 0.001; Figure 3a), but did not alter copper or zinc levels (Figure 
3b), consistent with the changes in brain levels of these metals in mice treated with lithium 
(Figure 2c). Lithium (10 mM) significantly inhibited the efflux of iron (chased after 59Fe 
loading) into the media (p < 0.001; Figure 3c), explaining the retention of iron. As expected, 
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lithium treatment (10 mM) had no effect on zinc retention in primary neurons treated with radio-
labeled 65Zn (p = 0.176, Supplementary Figure 8). 
The activities of both inositol monophosphatase (IMPase) and GSK-35 are considered 
molecular targets for lithium’s therapeutic effect in bipolar disorder3. L-690,330, a potent and 
more specific inhibitor of IMPase76, had no effect on cellular iron level during the 18 hour 
incubation (p = 0.106; Supplementary Figure 9a), thus eliminating IMPase in the mechanism 
of iron accumulation induced by lithium. However, 6-bromoindirubin-3'-oxime (BIO), a potent 
and specific inhibitor of GSK-377, caused iron retention similar to the effect of lithium (+59%, 
p=0.002, Supplementary Figure 9b). 
Both lithium and BIO are reported to decrease total tau protein levels in addition to their 
inhibitory effects of GSK in cultured neurons42. In agreement with previous reports41, 42, we 
found that lithium (≥5 mM, 18 hours) suppresses tau protein levels in primary neurons (5mM Li: 
-48%, p = 0.007; 10mM Li: -35%, p = 0.034; Figure 3d) and in SH-SY5Y cells (5mM Li: -25%, 
p = 0.003; 10mM Li: -25%, p = 0.002; Supplementary Figure 10a-b). BIO (18 hours) also 
suppressed tau protein levels in primary neuronal culture (1M BIO: -25%, p = 0.043; 2M 
BIO: -26%, p = 0.048; Supplementary Figure 10c-d), which may be the mechanism for its 
ability to increase neuronal iron levels. 
To demonstrate the requirement for tau in the mechanism of lithium-induced iron 
accumulation in neurons, lithium (10 mM, 18 hours) was administered to tau knockout primary 
neurons and compared with background-matched wild type neurons (Figure 3e). As previously 
shown43, tau KO neurons retained more iron (+20%, p = 0.032) compared to wild type neurons. 
As expected, lithium treatment (10 mM, 18 hours) of wild type neurons induced a significant 
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accumulation of iron (+20%, p = 0.038), but lithium treatment of tau knockout neurons induced 
no further iron accumulation. Thus, lithium-induced neuronal iron accumulation requires the 
expression of tau protein. 
Tau knockout and APP knockout mice are resistant to neurodegeneration caused by chronic 
lithium administration 
Tau mediates neuronal iron efflux by facilitating the trafficking of APP to the cell surface, 
where it stabilizes the iron export channel ferroportin43, 52-54. To test whether lithium-induced 
iron accumulation requires APP, we applied the same lithium treatment to tau knockout mice, 
APP knockout mice, and their background-matched wild type mice. We studied mice at 3-
months of age, because the knockouts have yet to develop the age-dependent elevation in brain 
iron levels43, 44.  
All three strains showed no weight reduction during 21 days of lithium treatment (Figure 4a) 
even though APP knockout were lighter in weight (as reported previously78). Lithium treatment 
predictably caused an elevation in mouse plasma lithium levels (WT: +6.6 fold, p < 0.001; tau 
KO: +6.7 fold, p < 0.001; APP KO: +4.3 fold, p = 0.007; Figure 4b), although the levels in all 
three strains remained well below the lower limit of the therapeutic concentration range40. As 
with the Bl6/C57J mice (Figure 2c), lithium treatment induced iron elevation in both the cortex 
and SN of the littermate Bl6/129Sv mice (cortex: +15%, p = 0.031; SN: +20%, p = 0.041), but 
despite lithium elevations in brain regions being commensurate to those in Bl6/C57J mice 
(Figure 2b), tau- and APP- knockout mice were unaffected (Figure 4c-d), consistent with the 
neuronal culture findings (Figure 3e). Brain copper or zinc levels were again unaffected 
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(Supplementary Figure 11a-d), and iron levels in the cerebellum and liver were unaltered 
(Supplementary Figure 11e-f), by lithium treatment in all three strains.  
Ablation of APP abolished lithium-induced iron accumulation (Figure 4c-d), despite soluble 
tau protein levels in cortex and SN of APP knockout mice treated with lithium being suppressed 
comparably to wild type (cortex: -19%, p = 0.041 for wild type and -41%, p = 0.006 for APP 
KO; SN: -42%, p < 0.001 for wild type and 21%, p = 0.041 for APP KO; Figure 4e, Figure 4f, 
Supplementary Figure 12). These results confirm our prediction that lithium-induced brain iron 
accumulation requires both tau and APP expression, with tau being upstream in the APP-
associated iron homeostatic pathway. 
As lithium-induced Parkinson-like symptoms such as hand tremor may be mediated by iron 
accumulation in the brain, disabling lithium-induced SN iron accumulation in tau and APP 
knockout mice (Figure 4d) should also prevent motor deficits and SN neuronal loss. Indeed, 
lithium-induced motor deficits were abolished in tau and APP knockout mice, as evidenced by 
unaffected time to turn (WT, p = 0.020; Figure 4g) and time to finish (WT, p = 0.048; 
Supplementary Figure 13a) in the Pole test, and unaltered average distance per movement 
(WT, p = 0.049; Figure 4h), distance of locomotion (WT, p = 0.020; Supplementary Figure 
13b), and velocity (WT, p = 0.048; Supplementary Figure 13c) in the Open field test. 
Untreated APP knockout mice did show baseline motor deficits (Figure 4g-h, Supplementary 
Figure 13a-c), as previously reported78, but these were not worsened by lithium. Tau or APP 
ablation also negated SN dopaminergic neuron loss induced by lithium treatment (WT, p < 
0.001; Figure 4i, Supplementary Figure 14a). Together, these results support the conclusion 
that lithium-induced parkinsonism is mediated by iron accumulation, which is tau- and APP- 
dependent. 
 23
Since lithium treatment also increases cortical iron levels (Figures 2c & 4c), we investigated 
its effect on cognitive performance and related brain anatomy. In the Y-maze test, we found the 
memory performance of wild type mice was markedly impaired by 21 days of lithium treatment 
(p = 0.022), but, as with the Pole test (Figure 4g), tau- and APP- KO mice were unaffected by 
lithium (Figure 4j). Accordingly, lithium treatment caused brain atrophy in wild type mice, 
evidenced by enlarged lateral ventricular area (+72%, p = 0.023; Figure 4k,l), shrinkage of CPu 
area (-13%, p = 0.011; Supplementary Figure 14b), and reduced cortical thickness (-7%, p = 
0.040; Supplementary Figure 14c), without affecting corpus callosum width (Supplementary 
Figure 14d). Again, lithium did not induce brain atrophy in tau- or APP- KO mice (Figure 4l, 
Supplementary Figure 14c,d). These toxic consequences of lithium administration to cortical 
thickness are in agreement with a previous report that found cortical neuronal apoptosis in mice 
upon chronic lithium treatment17. 
Discussion 
Lithium has an established record of efficacy in bipolar affective disorder, despite a narrow 
therapeutic window limited by various toxicities of uncertain mechanism. Here we found that 
lithium may contribute to nigral and cortical degeneration, with motor and cognitive impairment 
in wild-type mice, recapitulating the neurophysiological and neurochemical phenotypes of aged 
tau knockout mice43, 44. Lithium suppresses tau protein levels in cultured neurons and in mice, 
causing iron accumulation through a tau- and APP-dependent interaction. The T2 relaxation time 
changes in the human lithium trial are consistent with iron elevation in hippocampus and SN. 
Although homeostasis keeps brain iron levels stringently stable in health, and geared to resist 
depletion79, rodent studies have shown that nearly 10% of brain iron is in relatively rapid 
exchange with dietary iron52, 80, indicating that in order to prevent iron accumulation, iron efflux 
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from the brain must be constantly active. It is this mechanism that lithium inhibits, by, at least in 
part, suppressing tau expression. Tau knockout mice develop iron-induced neurodegenerative 
changes at 12 months of age 43, 44 but lithium-induced toxic iron accumulation occurs within 
weeks. This is probably because the tau knockout mice in youth have the benefit of upregulated 
compensatory responses from other microtubule associated proteins 45 in contrast to the more 
acute suppression of tau expression by lithium treatment. Our findings add to the evidence that 
lithium at therapeutic (and eventually even at subtherapeutic) chronic doses can cause 
neurodegeneration17, and provide a possible mechanism for adverse neurological effects in 
susceptible individuals.  
Parkinsonism is an uncommon adverse effect of lithium treatment, but hand tremor is 
common and may be age- and dose- dependent 81-83. In addition, lithium use was found to be 
associated with an increased incidence of antiparkinson drug use or a PD diagnosis16. The 
mechanisms underlying these motor abnormalities are not known, but could be due to persistent 
or transient extrapyramidal syndromes caused by damage to the basal ganglia and SN. Iron may 
play a critical role in promoting SN pathology in PD55, 84, and our findings demonstrate how 
lithium could worsen iron-mediated SN damage. SN iron accumulation in trial subjects may have 
occurred after only 3 months of low-dose lithium treatment (Figure 1b), although no 
conspicuous motor abnormalities were reported in this group. Additionally, our findings in mice 
support the possibility that lithium-induced parkinsonism can become irreversible in a proportion 
of patients6-8, 11, 15. 
Unexpectedly, we found that lithium treatment at doses inducing blood levels well below the 
human therapeutic range caused cognitive impairment and brain atrophy in mice after 3 weeks 
(Figure 4j-l). It has been shown previously that lithium treatment at therapeutic doses can cause 
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cortical neuronal apoptosis17, which may explain our findings. While lithium treatment was 
previously reported to correct the smaller hippocampal volumes in patients with bipolar 
disorder85, there is also evidence that long-term lithium treatment is associated with cognitive 
impairment86-89 and brain atrophy89. Neurodegeneration in mice administered lithium to achieve 
blood levels that are easily tolerated by humans may reflect different pharmacodynamics in the 
species, or that humans are less sensitive than mice to lithium-induced neurotoxicity. 
Lithium-induced motor deficits in mice are reported to involve the calcineurin/nuclear factor 
of activated T cells (NFAT)/Fas ligand signaling pathway, and prevented by inhibition of 
calcineurin, or knockout of Fas17. Iron modulates calcineurin activity90, 91, and can thereby 
impact the NFAT/Fas signaling pathway. Treatment with iron dramatically elevates NFAT 
activity92, 93 while administering the iron chelator deferoxamine abolishes iron-induced NFAT 
activation92, 93. Together with our current data, a proposed model pathway emerges (Figure 5) 
where lithium suppresses tau protein levels, thus preventing APP trafficking to the cell surface 
and resulting in neuronal iron retention. In turn, this activates calcineurin/NFAT/Fas signaling, 
induces cortical and nigral neuronal apoptosis and engenders motor and cognitive disability. 
Lithium was an attractive drug candidate for AD since its target, GSK-3, regulates both A 
production and tau phosphorylation5. However, it is neither a potent nor specific inhibitor of 
GSK-394. In fact, neuronal deficits have been reported to result from both genetic reduction and 
specific inhibition of GSK-395, 96, highlighting the risk of inhibiting this enzyme97. Lithium 
arrests neuropathology in some AD rodent models36, 38, 39, but these are aggressive models driven 
by transgene overexpression, where the benefits of lithium inhibiting a dominant pathological 
target (e.g. tau hyperphosphorylation) outweigh lithium-induced neurotoxicity. The lithium-
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induced neurotoxicity that we, and others17, 39, observed might only be detected in normal mice 
or mice that do not express a neuropathology that is inhibited by lithium. 
Our current study might help explain the failure of trials of lithium for AD40, 98 and ALS99-101, 
both diseases where elevated iron in the affected tissue has been implicated in pathogenesis52, 102-
104. Despite the neurotoxicity in mice that our studies have elaborated, clinical lithium 
pharmacotherapy has predominantly neurotrophic benefits in the treatment of bipolar disorder. It 
is an intriguing hypothesis to consider that these benefits might be related to the correction of 
iron deficiency in certain brain regions. 
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Figure legends 
Figure 1. T2 relaxation time reductions in the SN of participants treated with lithium. a) 
Representative MRI images from treatment as usual (top) and lithium (bottom) ultra high risk 
groups. Arrow indicates the SN. b) Significant reduction in T2 relaxation time was found in 
lithium-treated subjects (p<0.001 compared to treatment as usual controls; p=0.007 compared to 
pre-treated scan, two-tailed t-test). Dotted line indicates values of baseline scan. n[treatment as 
usual]=9, n[lithium]=11. Means ± SEM are shown. *** p<0.001 (versus treatment as usual), ## 
p<0.01 (versus pre-scan). 
Figure 2. Lithium induces brain iron elevation and parkinsonism in mice. a) Lithium 
treatment did not induce a change in mouse weight, monitored daily as an index of animal health. 
b) Lithium treatment elevated levels in mouse brain and liver (p<0.001 for Ctx, SN, Cereb, or 
Liver, two-tailed t-test). c) Li treatment induced iron elevation in cerebral regions (p=0.008 for 
cortex, Ctx; p=0.039 for SN; two-tailed t-test) but not cerebellum (Cereb), liver, or plasma. d) 
Iron levels in SN correlate with lithium levels in Li-treated mice (R2=0.62, p=0.007, linear 
regression) but not sham-treated mice (R2=0.02, p=0.702, linear regression).e) Quantification of 
western blots showed reduction of tau in cortex (p=0.032, two-tailed t-test) and SN (p<0.001, 
two-tailed t-test) of Li-treated mice compared to sham-treated mice. f) Following 21 days 
exposure, Li-treated mice took longer to turn (p=0.008, two-tailed t-test) in the Pole test. g) Li-
treated mice maintained less time on the rod compared to sham-treated mice (p=0.004, two-tailed 
t-test). n=12 per treatment group. h-i) Representative TH-staining of sham- (top) and Li- 
(bottom) treated mice. Quantitative data are shown in i. Significant reduction was found in TH-ir 
neurons in the SN of Li-treated mice (p<0.001, two-tailed t-test). n=5 per treatment group. j) 
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Significant reductions were found in the striatal dopamine levels (p=0.023, two-tailed t-test), 
measured by HPLC in Li-treated mice. n=12 per treatment group. Means ± SEM are shown. * 
p<0.05, ** p<0.01, *** p<0.001. 
Figure 3. Li-induced iron elevation is caused by tau reduction in primary neuronal culture. 
a) Li treatment to neurons for 18 h induced dose-dependent 59Fe retention (p=0.005 for 5mM Li, 
p<0.001 for 10mM Li, one-way ANOVA, n=4 per treatment). b) Li treatment of neurons for 18h 
induced specific iron elevation (p<0.001, two-tailed t-test, n=6 per treatment), without altering 
copper or zinc. c) Li treatment (10 mM) inhibited iron export (p<0.001, non-linear regression 
with extra sum-of-squares F test, n=6 per group). d) Li treatment reduced neuronal tau levels 
(representative blots shown beneath) at 5mM (p=0.007) and 10mM (p=0.034, one-way ANOVA) 
after 18 h. n=4 per group. e) Tau knockout neurons retained more 59Fe iron (p=0.032) (18 h), but, 
in contrast to wild type neurons, were resistant to Li-induced iron accumulation (p=0.038, two-
way ANOVA). n=4 per group. Each experiment was independently repeated three times. Means 
± SEM are shown. * p<0.05, ** p<0.01, *** p<0.001. 
Figure 4. Li-induced parkinsonism is mediated by tau and APP. a) Daily mean weights of 
the mouse cohorts revealed no significant impact of lithium treatment within each genotype 
group during the course of study. APP knockout mice were lighter, as reported previously78. b) 
Li treatment significantly elevated plasma lithium levels of 3-month-old wild type (p<0.001, 
Two-way ANOVA with post-hoc Dunnett’s test), tau knockout (p<0.001), and APP knockout 
(p=0.007) mice. These concentrations are well below the usual therapeutic range of clinical 
lithium therapy. c-d) Elevated iron levels were observed in the cortex (c, p=0.031, two-way 
ANOVA with post-hoc Dunnett’s test) and SN (d, p=0.041) of Li-treated wild type mice, but 
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loss of tau or APP abolished the elevation. e-f) Li treatment induced tau reduction in cortex and 
SN of both wild type (e, p=0.041 for cortex, p<0.001 for SN, two-tailed t-test) and APP 
knockout mice (f, p=0.006 for cortex, p=0.041 for SN, two-tailed t-test). g-h) Li-treated wild 
type mice required longer time to turn in the Pole test (g, p=0.020, two-way ANOVA with post-
hoc Dunnett’s test) and showed significantly reduced average distance per movement in the 
Open field test (h, p<0.001), but loss of tau or APP protected against Li-induced motor 
impairment. i) Li treatment caused SN dopaminergic neuron loss (p<0.001, two-way ANOVA 
with post-hoc Dunnett’s test), but did not cause similar neuronal loss in tau knockout or APP 
knockout mice. j) Li treatment impaired cognitive function of wild type mice, evidenced by 
significantly reduced novel arm duration in the Y maze test (p=0.022, two-tailed t-test). Such 
impairment was not evident in tau knockout and APP knockout mice. k) Representative coronal 
section of cerebrum of wild type mice treated with sham (left) or Li (right). Arrow indicates the 
landmark used to identify the section. Lines indicate the area quantified. l) Significant 
enlargement of LV was found in Li-treated wild type mice (p=0.023, two-way ANOVA with 
post-hoc Dunnett’s test), but not in Li-treated tau knockout or APP knockout mice. n=9-11 per 
treatment group. Means ± SEM are shown. * p<0.05, ** p<0.01, *** p<0.001. 
Figure 5. A model of affected pathways for lithium-induced neurodegeneration. Lithium 
treatment suppresses soluble tau protein levels, which prevents APP trafficking to the neuronal 
surface. Lack of surface APP destabilizes ferroportin (Fpn), which results in iron accumulation. 
Elevated iron activates calcineurin/NFAT/Fas signaling, which then induces neuronal apoptosis, 
engendering motor and cognitive disability. 
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Supplementary Figure 1. T2 relaxation time in brain regions from subjects treated with lithium. 
a) Regions of interest were mapped as illustrated by an operator blinded to treatment group. 1. 
lateral ventricular area (LV); 2. Caudate; 3. lenticular nucleus (LN); 4. SN; 5. Hippocampus 
(previously reported1). b) No change in T2 relaxation time was found in the Caudate and LN of 
lithium-treated participants (p=0.18 for Caudate; p=0.29 for LN, two-tailed t-test). LV area was 
unaltered by Li treatment (p=0.177, two-tailed t-test). n[treatment as usual]=9, n[lithium]=11. 
Means ± SEM are shown. 
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Supplementary Figure 2. No changes in copper (a) or zinc (b) levels in tissues of Li-treated 
mice. Means ± SEM are shown, n=12 per treatment group. 
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Supplementary Figure 3. Correlations between bio-metals and Li in brain regions of Li-treated 
and sham-treated mice. a) Iron levels in cortex correlates with lithium levels in Li-treated mice 
(R2=0.439, p=0.026, linear regression) but not sham-treated mice (R2=0.0327, p=0.574, linear 
regression). b) No correlation between iron and lithium levels in cerebellum. c-d) No correlation 
between copper (c) or zinc (d) and lithium levels in cortex. n=12 per treatment group. 
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Supplementary Figure 4. Li treatment reduces phosphorylated tau levels in both cortex and SN. 
Quantification of western blot showed reduction of tau phosphorylation at Ser396 in cortex 
(p=0.034, two-tailed t-test) and SN (p=0.039, two-tailed t-test) of Li-treated mice compared to 
sham-treated mice. Means ± SEM are shown, n=12 per treatment group. * p<0.05. 
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Supplementary Figure 5. Additional locomotor deficits induced by Li treatment. a) Li-treated 
mice required longer time to finish (p=0.041, two-tailed t-test) in the Pole test after 21 days of 
treatment. b) Li-treated mice showed reduced maximum speed in the Rotarod test. Two-way 
ANOVA with post-hoc Dunnett’s test: speed (p< 0.001), and treatment (p< 0.001) effects but no 
interaction (p = 0.107). c-e) Li-treated mice showed reduced distance of locomotion (c, p=0.022, 
two-tailed t-test), reduced velocity (d, p=0.023), and reduced average distance per movement (e, 
p=0.018) in the Open field test. Means ± SEM are shown, n=12 per treatment group. * p<0.05, 
*** p<0.001. 
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Supplementary Figure 6. Li-induced motor impairment is independent of its sedative effect. a) 
Neither a single dose of Li (3.6mg/kg, gavage) nor diazepam (3mg/kg, gavage) significantly 
altered the performance of mice in the Rotarod test 2 hours post-dose. b) Diazepam sedated mice 
within 20 minutes, evidenced by decreased locomotion in the Open field test 20 minutes after the 
dose was delivered, however no such effect was found following the lithium dose. Means ± SEM 
are shown, n=5 per treatment group. Both experiments tested for significance with two-way 
ANOVA and post-hoc Dunnett’s test. ** p=0.0064. 
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Supplementary Figure 7. Li treatment selectively affects dopaminergic neurons in the SN. a) 
No significant reduction (p=0.821, two-tailed t-test) was found in TH-negative, Neutral Red-
positive neurons in the SN of Li-treated mice. n=5 per treatment group. b) Significant reductions 
were found in the striatal DOPAC levels (p=0.024, two-tailed t-test). n=12 per treatment group. 
Means ± SEM are shown. * p<0.05. 
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Supplementary Figure 8. Lithium treatment does not alter 65Zn retention in primary neurons 
(p=0.176 for 10mM Li, two-tailed t-test). Means ± SEM are shown, n=4 per group. 
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Supplementary Figure 9. Iron accumulation is induced GSK-3 inhibition. a) No 59Fe retention 
was found after L690,330 (p=0.106, one-way ANOVA with post-hoc Dunnett’s test) treatment. 
b) Significant 59Fe retention was found after BIO treatment (p=0.002, one-way ANOVA with 
post-hoc Dunnett’s test). Each experiment was independently repeated three times. Means ± 
SEM are shown, n=4 per group. * p<0.05. 
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Supplementary Figure 10. Li and BIO (18h incubation) suppress tau protein levels. a) 
Representative tau western blots from lithium-treated SH-SY5Y cells. b) Quantification of (a) 
showed lowering of tau with 5 mM (p=0.003, one-way ANOVA with post-hoc Dunnett’s test) or 
10 mM (p=0.002) Li treatment. c) Representative western blot for tau from BIO-treated primary 
neurons. d) Quantification of (c) showed that BIO lowered tau levels (p=0.043 for 1 M and 
p=0.048 for 2 M, one-way ANOVA with post-hoc Dunnett’s test). Means ± SEM are shown, 
n=4 per group, and the experiments were independently repeated three times. * p<0.05, ** 
p<0.01. 
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Supplementary Figure 11. No changes in (a) cortex copper, (b) cortex zinc, (c) SN copper, (d) 
SN zinc, (e) cerebellum iron, or (f) liver iron levels in tissues of Li-treated mice, regardless of 
genotype. Means ± SEM are shown, n=9-11 per treatment group. 
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Supplementary Figure 12. Representative western blot images of cortex and SN tau protein in 
wild type and APP knockout mice. 
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Supplementary Figure 13. Additional motor deficits in wild type mice induced by Li treatment. 
a-c) Li-treated wild type mice required longer time to finish [a; two-way ANOVA with post-hoc 
Dunnett’s test: genotype (p= 0.014), and treatment (p< 0.001) effects but no interaction (p= 
0.283)] in the Pole test, showed reduced distance of locomotion [b; genotype (p< 0.001), but no 
treatment (p= 0.368) effects nor interaction (p= 0.501)], and reduced velocity [c; genotype (p< 
0.001), but no treatment (p= 0.361) effects nor interaction (p= 0.500)] in the Open field test, but 
loss of tau or APP protected against Li-induced motor impairment. APP knockout mice showed 
motor deficits themselves, evidenced by reduced distance of locomotion (p< 0.001), and reduced 
velocity (p< 0.001). Li treatment did not further worsen the phenotype. Means ± SEM are shown, 
n=9-11 per treatment group. * p<0.05, *** p<0.001. 
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Supplementary Figure 14. Other neuroanatomical changes induced by Li. a) No significant 
reduction was found in TH-negative, Neutral Red-positive neurons in the SN of Li-treated mice. 
b-c) Li treatment reduced CPu size [b; two-way ANOVA with post-hoc Dunnett’s test: no 
genotype (p= 0.606) or treatment (p= 0.153) effects, but interaction (p= 0.017)] and cortical 
thickness [c; genotype (p= 0.041) and interaction (p= 0.043) effects, but no treatment (p= 0.371) 
effect] in wild type mice, but the effect was abolished by loss of tau or APP. d) No change in 
corpus callosum thickness was detected in all three mouse strains. Means ± SEM are shown, 
n=9-11 per treatment group. * p<0.05, ** p<0.01. 
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